This excerpt taken from the ARIA 8-K filed May 7, 2008.
2008 Corporate Objectives
In the first quarter of 2008, ARIAD continued to build upon its progress in 2007. The Company is on track to deliver on all of its global development plan initiatives for deforolimus with its strategic partner Merck and independently for its AP24534 program. These initiatives include ongoing enrollment in the SUCCEED Phase 3 clinical trial of deforolimus in patients with metastatic sarcomas, the expansion of the global development of deforolimus to include patients with additional solid tumors and the initiation of Phase 1 studies for ARIAD’s second oncology product candidate, AP24534, the first of which is expected to start enrolling patients this month.